Palisade Bio Presents Development Overview for Moderate-to-Severe Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it presented at IBD Innovate: Product Development for Crohn’s & Colitis held April 9-10, 2024, in Cambridge, MA.
As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the company’s research partner, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral presentation titled Advancing PALI-2108: Discovery to Strategy Positioning, which discussed the development of PALI-2108, its differentiation and positioning in the competitive landscape as well as a clinical pathway towards late-stage development. The presentation is accessible on the Publications page under the Science section of Palisade Bio’s website, www.palisadebio.com.
“We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108. We continue to generate a growing body of data from PALI-2108 for the treatment of UC and remain on track to launch our Phase 1 clinical study later this year,” commented Dr. Jones.
As previously announced, the development of PALI-2108 is supported by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.
PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.
The Crohn’s & Colitis Foundation seeks to accelerate the discovery and development of novel products with the potential to address the unmet needs of patients with IBD. In pursuit of this objective, the foundation launched IBD Ventures to directly fund product discovery and development. IBD Innovate is the premier IBD product development conference for therapeutics, diagnostics, devices, and digital health.
Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, visit www.palisadebio.com.
Total Page Views: 588
